Uterine Balloon Tamponade
Postpartum hemorrhage (PPH) is the leading direct cause of maternal death worldwide. PPH can be prevented and treated, but if standard methods fail or are not available, women in low-resource settings may not have access to additional care. Uterine balloon tamponade (UBT) has been recognized as a relatively easy-to-use and effective second-line option for managing severe PPH, but cost and other factors limit its use in low-resource settings. With further research and development, a lower-cost, appropriate UBT device has the potential to vastly improve treatment for PPH and save women’s lives.
Read or print the entire technology opportunity assessment (146 KB PDF).
Funding for this technology assessment was provided by Merck.